Tct 2022: symplicity htn-3 trial data show sustained long-term blood pressure reductions with medtronic renal denervation procedure

Long-term analysis from landmark renal denervation trial presented as late breaking clinical science, published simultaneously in the lancet data add to growing body of evidence supporting the durability of the symplicity blood pressure procedure dublin and boston , sept. 18, 2022 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced long-term results from the symplicity htn-3 clinical trial.
MDT Ratings Summary
MDT Quant Ranking